Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care? July 25, 2025Vol.51 No.29By Sara Willa Ernst
Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya July 25, 2025Vol.51 No.29By Claire Marie Porter
Sponsored City of Hope brings evidence-based approaches to integrative oncology July 25, 2025Vol.51 No.29By Richard T. Lee
PodcastThe Directors The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentumAs oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic July 18, 2025Vol.51 No.28By Paul Goldberg and Katie Goldberg
Regulatory News ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population July 18, 2025Vol.51 No.28By Jacquelyn Cobb and Sara Willa Ernst
Sponsored Imaging’s ride to the bottom in clinical trials—and why it matters now July 18, 2025Vol.51 No.28By Jeff Sorenson
First-ever financial toxicity tumor board aims to change the standard of careResearchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI July 11, 2025Vol.51 No.27By Claire Marie Porter
Conversation with The Cancer Letter HHS seems poised to exert control over USPSTFRansohoff: The task force is the pinnacle of evidence-based medicine July 11, 2025Vol.51 No.27By Paul Goldberg
Guest Editorial Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities July 11, 2025Vol.51 No.27By Robert Peter Gale
